Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64


The phosphatase UBASH3B/Sts-1 is a negative regulator of Bcr-Abl kinase activity and leukemogenesis.

Mian AA, Baumann I, Liebermann M, Grebien F, Superti-Furga G, Ruthardt M, Ottmann OG, Hantschel O.

Leukemia. 2019 Apr 8. doi: 10.1038/s41375-019-0468-y. [Epub ahead of print] No abstract available.


Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential.

Kidan N, Khamaisie H, Ruimi N, Roitman S, Eshel E, Dally N, Ruthardt M, Mahajna J.

J Cancer. 2017 Oct 23;8(19):3952-3968. doi: 10.7150/jca.19633. eCollection 2017.


BCR: a new target in resistance mediated by BCR/ABL-315I?

Haberbosch I, Rafiei A, Oancea C, Ottmann GO, Ruthardt M, Mian AA.

Genes Cancer. 2016 Jan;7(1-2):36-46.


Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.

Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.

BMC Cancer. 2016 Feb 23;16:140. doi: 10.1186/s12885-016-2182-8.


The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.

Rafiei A, Mian AA, Döring C, Metodieva A, Oancea C, Thalheimer FB, Hansmann ML, Ottmann OG, Ruthardt M.

PLoS Genet. 2015 Apr 28;11(4):e1005144. doi: 10.1371/journal.pgen.1005144. eCollection 2015 Apr.


STAT activation status differentiates leukemogenic from non-leukemogenic stem cells in AML and is suppressed by arsenic in t(6;9)-positive AML.

Oancea C, Rüster B, Brill B, Roos J, Heinssmann M, Bug G, Mian AA, Guillen NA, Kornblau SM, Henschler R, Ruthardt M.

Genes Cancer. 2014 Nov;5(11-12):378-92.


PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.

Mian AA, Rafiei A, Haberbosch I, Zeifman A, Titov I, Stroylov V, Metodieva A, Stroganov O, Novikov F, Brill B, Chilov G, Hoelzer D, Ottmann OG, Ruthardt M.

Leukemia. 2015 May;29(5):1104-14. doi: 10.1038/leu.2014.326. Epub 2014 Nov 14.


5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia.

Roos J, Oancea C, Heinssmann M, Khan D, Held H, Kahnt AS, Capelo R, la Buscató E, Proschak E, Puccetti E, Steinhilber D, Fleming I, Maier TJ, Ruthardt M.

Cancer Res. 2014 Sep 15;74(18):5244-55. doi: 10.1158/0008-5472.CAN-13-3012. Epub 2014 Jul 31.


Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013.


Oleylamine-carbonyl-valinol inhibits auto-phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines.

Najajreh Y, Khamaisie H, Ruimi N, Khatib S, Katzhendler J, Ruthardt M, Mahajna J.

Mol Biol Rep. 2013 Mar;40(3):2205-13. doi: 10.1007/s11033-012-2282-8. Epub 2012 Dec 5.


Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.

Khateb M, Ruimi N, Khamisie H, Najajreh Y, Mian A, Metodieva A, Ruthardt M, Mahajna J.

BMC Cancer. 2012 Nov 27;12:563. doi: 10.1186/1471-2407-12-563.


Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I.

Mian AA, Metodieva A, Badura S, Khateb M, Ruimi N, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

BMC Cancer. 2012 Sep 17;12:411. doi: 10.1186/1471-2407-12-411.


Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells.

Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M, Bug G.

Cell Cycle. 2012 Sep 1;11(17):3219-26. doi: 10.4161/cc.21565. Epub 2012 Aug 16.


p185(BCR/ABL) has a lower sensitivity than p210(BCR/ABL) to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia.

Mian AA, Metodieva A, Najajreh Y, Ottmann OG, Mahajna J, Ruthardt M.

Haematologica. 2012 Feb;97(2):251-7. doi: 10.3324/haematol.2011.047191. Epub 2011 Nov 4.


The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells.

Rettinger E, Kuçi S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P.

Cytotherapy. 2012 Jan;14(1):91-103. doi: 10.3109/14653249.2011.613931. Epub 2011 Oct 6.


Sulindac sulfide reverses aberrant self-renewal of progenitor cells induced by the AML-associated fusion proteins PML/RARα and PLZF/RARα.

Steinert G, Oancea C, Roos J, Hagemeyer H, Maier T, Ruthardt M, Puccetti E.

PLoS One. 2011;6(7):e22540. doi: 10.1371/journal.pone.0022540. Epub 2011 Jul 19.


Oleic acid is the active component in the mushroom Daedalea gibbosa inhibiting Bcr-Abl kinase autophosphorylation activity.

Khamaisie H, Sussan S, Tal M, Najajreh Y, Ruthardt M, Mahajna J.

Anticancer Res. 2011 Jan;31(1):177-83.


The t(6;9) associated DEK/CAN fusion protein targets a population of long-term repopulating hematopoietic stem cells for leukemogenic transformation.

Oancea C, Rüster B, Henschler R, Puccetti E, Ruthardt M.

Leukemia. 2010 Nov;24(11):1910-9. doi: 10.1038/leu.2010.180. Epub 2010 Sep 9.


The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4.

Bursen A, Schwabe K, Rüster B, Henschler R, Ruthardt M, Dingermann T, Marschalek R.

Blood. 2010 Apr 29;115(17):3570-9. doi: 10.1182/blood-2009-06-229542. Epub 2010 Mar 1.


5-lipoxygenase: underappreciated role of a pro-inflammatory enzyme in tumorigenesis.

Steinhilber D, Fischer AS, Metzner J, Steinbrink SD, Roos J, Ruthardt M, Maier TJ.

Front Pharmacol. 2010 Dec 24;1:143. doi: 10.3389/fphar.2010.00143. eCollection 2010.


Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment.

Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M.

PLoS One. 2009 Oct 30;4(10):e7661. doi: 10.1371/journal.pone.0007661.


Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL.

Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M.

Leukemia. 2009 Dec;23(12):2242-7. doi: 10.1038/leu.2009.194. Epub 2009 Oct 1.


Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome.

Boehrer S, Adès L, Tajeddine N, Hofmann WK, Kriener S, Bug G, Ottmann OG, Ruthardt M, Galluzzi L, Fouassier C, Tailler M, Olaussen KA, Gardin C, Eclache V, de Botton S, Thepot S, Fenaux P, Kroemer G.

Oncogene. 2009 Jun 4;28(22):2205-18. doi: 10.1038/onc.2009.69. Epub 2009 Apr 27.


The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR/ABL.

Mian AA, Schüll M, Zhao Z, Oancea C, Hundertmark A, Beissert T, Ottmann OG, Ruthardt M.

Leukemia. 2009 Sep;23(9):1614-21. doi: 10.1038/leu.2009.69. Epub 2009 Apr 16.


The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.

Gwanmesia PM, Romanski A, Schwarz K, Bacic B, Ruthardt M, Ottmann OG.

BMC Cancer. 2009 Feb 13;9:53. doi: 10.1186/1471-2407-9-53.


Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR/ABL.

Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, Ruthardt M.

Int J Cancer. 2008 Jun 15;122(12):2744-52. doi: 10.1002/ijc.23467.


The aorta-gonad-mesonephros-derived stroma cell line DAS104-4 induces differentiation of leukemic cells.

Pramanik K, Trüpschuch S, Greiner A, Ruthardt M, Henschler R, Müller AM.

Leuk Res. 2008 May;32(5):781-9. Epub 2007 Nov 5.


Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.

Nowak D, Boehrer S, Hochmuth S, Trepohl B, Hofmann W, Hoelzer D, Hofmann WK, Mitrou PS, Ruthardt M, Chow KU.

Anticancer Drugs. 2007 Oct;18(9):981-95.


Effect of histone deacetylase inhibitor valproic acid on progenitor cells of acute myeloid leukemia.

Bug G, Schwarz K, Schoch C, Kampfmann M, Henschler R, Hoelzer D, Ottmann OG, Ruthardt M.

Haematologica. 2007 Apr;92(4):542-5.


Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.

Zheng X, Seshire A, Rüster B, Bug G, Beissert T, Puccetti E, Hoelzer D, Henschler R, Ruthardt M.

Haematologica. 2007 Mar;92(3):323-31.


INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.

Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T.

Blood. 2007 Jan 1;109(1):306-14. Epub 2006 Sep 5.


Prostate-apoptosis-response-gene-4 increases sensitivity to TRAIL-induced apoptosis.

Boehrer S, Nowak D, Puccetti E, Ruthardt M, Sattler N, Trepohl B, Schneider B, Hoelzer D, Mitrou PS, Chow KU.

Leuk Res. 2006 May;30(5):597-605. Epub 2006 Mar 2.


Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.

Bug G, Ritter M, Wassmann B, Schoch C, Heinzel T, Schwarz K, Romanski A, Kramer OH, Kampfmann M, Hoelzer D, Neubauer A, Ruthardt M, Ottmann OG.

Cancer. 2005 Dec 15;104(12):2717-25.


The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.

Puccetti E, Zheng X, Brambilla D, Seshire A, Beissert T, Boehrer S, Nürnberger H, Hoelzer D, Ottmann OG, Nervi C, Ruthardt M.

Cancer Res. 2005 Jul 15;65(14):6080-8.


Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.

Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T, Boehrer S, Hoelzer D, Ottmann OG, Ruthardt M.

Cancer Res. 2005 Apr 1;65(7):2537-41.


In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis.

Boehrer S, Brieger A, Schaaf S, Kukoc-Zivojnov N, Nowak D, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Leuk Lymphoma. 2004 Jul;45(7):1445-51.


Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.

Kukoc-Zivojnov N, Puccetti E, Chow KU, Bergmann M, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E, Boehrer S.

Exp Hematol. 2004 Jul;32(7):649-56.


In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.

Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.

Biochem Pharmacol. 2004 Jul 1;68(1):85-93.


Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia.

Zang C, Liu H, Posch MG, Waechter M, Facklam M, Fenner MH, Ruthardt M, Possinger K, Phillip Koeffler H, Elstner E.

Leuk Res. 2004 Apr;28(4):387-97.


Acute promyelocytic leukemia: PML/RARalpha and the leukemic stem cell.

Puccetti E, Ruthardt M.

Leukemia. 2004 Jul;18(7):1169-75. Review.


Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.

Romanski A, Bacic B, Bug G, Pfeifer H, Gul H, Remiszewski S, Hoelzer D, Atadja P, Ruthardt M, Ottmann OG.

Haematologica. 2004 Apr;89(4):419-26.


Translocation products in acute myeloid leukemia activate the Wnt signaling pathway in hematopoietic cells.

Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, Sargin B, Köhler G, Stelljes M, Puccetti E, Ruthardt M, deVos S, Hiebert SW, Koeffler HP, Berdel WE, Serve H.

Mol Cell Biol. 2004 Apr;24(7):2890-904.


Gamma-catenin contributes to leukemogenesis induced by AML-associated translocation products by increasing the self-renewal of very primitive progenitor cells.

Zheng X, Beissert T, Kukoc-Zivojnov N, Puccetti E, Altschmied J, Strolz C, Boehrer S, Gul H, Schneider O, Ottmann OG, Hoelzer D, Henschler R, Ruthardt M.

Blood. 2004 May 1;103(9):3535-43. Epub 2004 Jan 22.


Leukemia-associated translocation products able to activate RAS modify PML and render cells sensitive to arsenic-induced apoptosis.

Puccetti E, Beissert T, Güller S, Li JE, Hoelzer D, Ottmann OG, Ruthardt M.

Oncogene. 2003 Oct 9;22(44):6900-8.


Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.

Beissert T, Puccetti E, Bianchini A, Güller S, Boehrer S, Hoelzer D, Ottmann OG, Nervi C, Ruthardt M.

Blood. 2003 Oct 15;102(8):2985-93. Epub 2003 Jun 26.


Expression and function of prostate-apoptosis-response-gene-4 in lymphatic cells.

Boehrer S, Chow KU, Ruthardt M, Hoelzer D, Mitrou PS, Weidmann E.

Leuk Lymphoma. 2002 Sep;43(9):1737-41.


AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor.

Puccetti E, Obradovic D, Beissert T, Bianchini A, Washburn B, Chiaradonna F, Boehrer S, Hoelzer D, Ottmann OG, Pelicci PG, Nervi C, Ruthardt M.

Cancer Res. 2002 Dec 1;62(23):7050-8.

Supplemental Content

Loading ...
Support Center